Apellis Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Apellis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Apellis Pharmaceuticals: 21 sponsored US clinical trials, 2 recruiting.
Apellis Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 13 completed. 8 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Membranoproliferative Glomerulonephritis, with 2 trials.
Top-decile sponsor footprint
Apellis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
NCT07215390
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05809531
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
NCT04572854
Pegcetacoplan Long Term Safety and Efficacy Extension Study
NCT03531255
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
NCT07214740
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05067127
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04579666
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
NCT04402060
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
NCT03777332
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
NCT03525600
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
NCT03525613
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03500549
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
NCT03453619
Pegcetacoplan (APL-2) in Neovascular AMD
NCT03465709
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
NCT03226678
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
NCT02503332
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
NCT02264639
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
NCT02461771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 8 |
What is open in the Apellis Pharmaceuticals pipeline
2 recruiting of 21 indexed (10% open); 13 completed (62%).
Phase mix: 8 late (III/IV) vs 12 early (I/II) (balanced across stages).
Top condition: Membranoproliferative Glomerulonephritis (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Apellis Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 21 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Apellis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
- Basilea Pharmaceutica · 21 trials · 14% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Hologic · 10% recruiting · 21 trials
- Southern Illinois University · 10% recruiting · 21 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
- Corewell Health East · 9% recruiting · 106 trials
Related
What to do with this Apellis Pharmaceuticals page
21 registered trials is a research-attention snapshot, not an endorsement of Apellis Pharmaceuticals or any single study.
- 2 of Apellis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Membranoproliferative Glomerulonephritis is the condition Apellis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Membranoproliferative Glomerulonephritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Apellis Pharmaceuticals pipeline card: 21 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.